MHC Class I Antigens In Malignant Cells Immune Escape And Response To Immunotherapy /
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeu...
שמור ב:
| Main Authors: | , , |
|---|---|
| מחבר תאגידי: | |
| פורמט: | אלקטרוני ספר אלקטרוני |
| שפה: | English |
| יצא לאור: |
New York, NY :
Springer New York : Imprint: Springer,
2013.
|
| מהדורה: | 1st ed. 2013. |
| סדרה: | SpringerBriefs in Cancer Research,
1 |
| נושאים: | |
| גישה מקוונת: | https://doi.org/10.1007/978-1-4614-6543-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
| LEADER | 04157nam a22005295i 4500 | ||
|---|---|---|---|
| 001 | 978-1-4614-6543-0 | ||
| 003 | DE-He213 | ||
| 005 | 20200702024358.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 130228s2013 xxu| s |||| 0|eng d | ||
| 020 | |a 9781461465430 |9 978-1-4614-6543-0 | ||
| 024 | 7 | |a 10.1007/978-1-4614-6543-0 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 614.5999 |2 23 |
| 100 | 1 | |a Aptsiauri, Natalia. |e author. |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 245 | 1 | 0 | |a MHC Class I Antigens In Malignant Cells |h [electronic resource] : |b Immune Escape And Response To Immunotherapy / |c by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera. |
| 250 | |a 1st ed. 2013. | ||
| 264 | 1 | |a New York, NY : |b Springer New York : |b Imprint: Springer, |c 2013. | |
| 300 | |a VIII, 51 p. 17 illus., 14 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a SpringerBriefs in Cancer Research, |x 2194-1173 ; |v 1 | |
| 505 | 0 | |a Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion. | |
| 520 | |a Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. . | ||
| 650 | 0 | |a Cancer research. | |
| 650 | 0 | |a Immunology. | |
| 650 | 0 | |a Molecular biology. | |
| 650 | 1 | 4 | |a Cancer Research. |0 https://scigraph.springernature.com/ontologies/product-market-codes/B11001 |
| 650 | 2 | 4 | |a Immunology. |0 https://scigraph.springernature.com/ontologies/product-market-codes/B14000 |
| 650 | 2 | 4 | |a Molecular Medicine. |0 https://scigraph.springernature.com/ontologies/product-market-codes/B1700X |
| 700 | 1 | |a Garcia-Lora, Angel Miguel. |e author. |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 700 | 1 | |a Cabrera, Teresa. |e author. |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781461465423 |
| 776 | 0 | 8 | |i Printed edition: |z 9781461465447 |
| 830 | 0 | |a SpringerBriefs in Cancer Research, |x 2194-1173 ; |v 1 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4614-6543-0 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||